#1 Clinical Trials Search in Europe

Povorcitinib

Povorcitinib, also known as INCB054707, is an investigational drug currently being studied in clinical trials for various skin conditions. These trials aim to evaluate the efficacy and safety of povorcitinib in treating disorders such as hidradenitis suppurativa, prurigo nodularis, vitiligo, and chronic spontaneous urticaria. The studies are designed to assess the drug’s effectiveness in improving symptoms, quality of life, and overall patient outcomes across different dosages and treatment durations.

Table of Contents

What is Povorcitinib?

Povorcitinib, also known by its research name INCB054707, is a new medication being studied for the treatment of various skin conditions[1]. It is currently undergoing clinical trials to evaluate its effectiveness and safety in treating several challenging skin disorders that often have limited treatment options.

What Conditions Does Povorcitinib Treat?

Povorcitinib is being investigated as a potential treatment for several skin conditions, including:

  • Hidradenitis Suppurativa (HS): A chronic, painful skin condition that causes lumps to form under the skin, typically in areas where skin rubs together[2][3][4]
  • Prurigo Nodularis: A skin disease characterized by itchy, firm bumps on the skin[5][6]
  • Nonsegmental Vitiligo: A condition where patches of skin lose their color[7][8]
  • Chronic Spontaneous Urticaria (CSU): Also known as chronic hives, this condition causes recurrent, itchy welts on the skin[9]

How Does Povorcitinib Work?

While the exact mechanism of action is not fully described in the provided clinical trial information, Povorcitinib is likely a type of medication known as a JAK inhibitor. JAK inhibitors work by blocking certain enzymes in the body that are involved in inflammation and immune responses. By doing so, they can help reduce symptoms in various inflammatory and autoimmune skin conditions[2][3].

How is Povorcitinib Administered?

Povorcitinib is taken orally in the form of a tablet. The dosage and frequency of administration may vary depending on the condition being treated and the specific clinical trial protocol[1][2].

Current Clinical Trials

Povorcitinib is currently being studied in several clinical trials:

  • Phase 3 trials for Hidradenitis Suppurativa[2][3][4]
  • Phase 3 trials for Prurigo Nodularis[5][6]
  • Phase 3 trials for Nonsegmental Vitiligo[7][8]
  • Phase 2 trial for Chronic Spontaneous Urticaria[9]
  • Phase 1 study to evaluate its effects on heart rhythm in healthy participants[10]

These trials are designed to assess the effectiveness and safety of Povorcitinib in treating these conditions.

Effectiveness of Povorcitinib

The effectiveness of Povorcitinib is still being evaluated in clinical trials. Some of the key measures being used to assess its effectiveness include:

  • For Hidradenitis Suppurativa: Reduction in the number of abscesses and inflammatory nodules, improvement in quality of life scores[2][3][4]
  • For Prurigo Nodularis: Reduction in itch intensity and improvement in skin lesions[5][6]
  • For Vitiligo: Repigmentation of affected skin areas, particularly on the face[7][8]
  • For Chronic Spontaneous Urticaria: Reduction in hive activity and itch severity[9]

The results of these trials will help determine how well Povorcitinib works for each condition.

Safety and Side Effects

As with all medications, researchers are carefully monitoring the safety of Povorcitinib during clinical trials. They are looking at:

  • The frequency, duration, and severity of side effects (called adverse events)[2][3][4]
  • Any serious side effects that may occur[2][3][4]
  • Effects on heart rhythm (QT interval)[10]

It’s important to note that the full safety profile of Povorcitinib is still being established through these clinical trials. Patients considering participation in a clinical trial should discuss potential risks and benefits with their healthcare provider.

Condition Study Duration Primary Outcome Measures Key Secondary Outcomes
Hidradenitis Suppurativa 54 weeks Proportion of participants achieving HiSCR Changes in abscess and inflammatory nodule counts, quality of life improvements
Prurigo Nodularis 24 weeks Proportion of participants achieving Itch NRS4 and IGA-CPG-S-TS Changes in itch intensity, quality of life, skin pain
Vitiligo 104 weeks Proportion of participants achieving F-VASI75 Changes in total body VASI, quality of life, patient-reported outcomes
Chronic Spontaneous Urticaria 36 weeks Change from baseline in UAS7 Proportion of participants achieving controlled disease, time to disease control

FAQ

  • What is povorcitinib? Povorcitinib, also known as INCB054707, is an investigational drug being studied for the treatment of various skin conditions. It is taken orally in tablet form.
  • What skin conditions is povorcitinib being studied for? Povorcitinib is being studied in clinical trials for hidradenitis suppurativa, prurigo nodularis, vitiligo, and chronic spontaneous urticaria.
  • How long do the clinical trials for povorcitinib typically last? The duration of clinical trials for povorcitinib varies depending on the condition being studied. Some trials last for 12 weeks, while others extend up to 52 or 104 weeks.
  • What are some common measures used in these clinical trials? Common measures include changes in disease-specific scores (e.g., HiSCR for hidradenitis suppurativa, VASI for vitiligo), quality of life assessments, and the proportion of participants achieving certain improvement thresholds.
  • Are there any side effects associated with povorcitinib in these trials? The trials are designed to monitor for Treatment-Emergent Adverse Events (TEAEs). Specific side effects are not mentioned in the provided information, as the studies are ongoing to evaluate the safety profile of povorcitinib.

Ongoing Clinical Trials on Povorcitinib

  • Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark France +7

  • Study on the Effects of Povorcitinib for Adults with Moderate to Severe Asthma Not Well Controlled

    Recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Germany Poland Spain

  • Study on the Effectiveness of Povorcitinib for Adults with Nonsegmental Vitiligo

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria France Germany Hungary Italy Poland

  • Study on the Effectiveness of Povorcitinib for Adults with Nonsegmental Vitiligo

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany The Netherlands Poland Spain

  • Study on the Effects and Safety of Povorcitinib for Adults with Chronic Spontaneous Urticaria

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Germany Poland

Glossary

  • Hidradenitis Suppurativa (HS): A chronic skin condition characterized by painful, inflamed lesions in areas where skin rubs together, such as the armpits, groin, and under the breasts.
  • Prurigo Nodularis: A skin condition characterized by hard, itchy lumps (nodules) that develop on the skin as a result of chronic scratching or picking.
  • Vitiligo: A condition in which the skin loses its pigment cells (melanocytes), resulting in white patches on different areas of the body.
  • Chronic Spontaneous Urticaria: A condition characterized by the appearance of itchy hives or welts on the skin that occur without an obvious trigger and last for more than six weeks.
  • HiSCR: Hidradenitis Suppurativa Clinical Response, a measure used to assess improvement in HS symptoms.
  • VASI: Vitiligo Area Scoring Index, a tool used to measure the extent and degree of depigmentation in vitiligo.
  • DLQI: Dermatology Life Quality Index, a questionnaire that measures how much a skin problem has affected a person's life over the previous week.
  • TEAE: Treatment-Emergent Adverse Event, any undesirable experience associated with the use of a medical product in a patient that appears or worsens during treatment.
  • Placebo-controlled: A study design where some participants receive an inactive substance (placebo) instead of the active drug, allowing researchers to compare the effects of the drug against no treatment.
  • Double-blind: A study design where neither the participants nor the researchers directly involved know who is receiving the active treatment and who is receiving the placebo.

References

  1. https://clinicaltrials.gov/study/NCT06505265
  2. https://clinicaltrials.gov/study/NCT06212999
  3. https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-povorcitinib-for-patients-with-moderate-to-severe-hidradenitis-suppurativa/
  4. https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-povorcitinib-for-patients-with-moderate-to-severe-hidradenitis-suppurativa-2/
  5. https://clinicaltrials.gov/study/NCT06516952
  6. https://clinicaltrials.gov/study/NCT06516965
  7. https://clinicaltrials.gov/study/NCT06113471
  8. https://clinicaltrials.gov/study/NCT06113445
  9. https://clinicaltrials.gov/study/NCT05936567
  10. https://clinicaltrials.gov/study/NCT06441318